Your Source for Leading Voices and Key Developments in EGFRm NSCLC

Trusted professionals delivering their expertise over popular topics from emerging data to pragmatic viewpoints.

Explore Leading Voices

Loading polls...

Clinical Updates Calendar

Anticipated Decisions

Approvals

Conferences

Designations

Events This Month

Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

Your Source for Leading Voices and Key Developments in EGFRm NSCLC

Home

Clinical Updates Calendar

View All Resources

Your Source for Leading Voices and Key Developments in EGFRm NSCLC

SAFFRON Data Reveal New Global SOC in EGFR+ NSCLC With MET Overexpression and/or Amplification After Osimertinib

SAFFRON Data Reveal New Global SOC in EGFR+ NSCLC with MET Overexpression and/or Amplification After Osimertinib

Sunvozertinib Now Available in the US for Previously Treated EGFR Exon 20 Insertion–Mutated NSCLC

DISCOVER TRENDING TAGS

Home

Clinical Updates Calendar

Get Updates

View All Resources